Taro Pharmaceutical Industries Ltd.
TARO

$1.62 B
Marketcap
$42.98
Share price
Country
$0.01
Change (1 day)
$45.76
Year High
$32.67
Year Low

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

marketcap

Revenue of Taro Pharmaceutical Industries Ltd. (TARO)

Revenue in 2024 (TTM): $629.18 M

According to Taro Pharmaceutical Industries Ltd.'s latest financial reports the company's current revenue (TTM) is $629.18 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Taro Pharmaceutical Industries Ltd.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2024 $629.18 M $304.98 M $38.4 M $82.67 M $53.87 M
2023 $572.95 M $268.32 M $52.65 M $38.21 M $25.45 M
2022 $561.35 M $293.12 M $164.89 M $77.86 M $58.27 M
2021 $548.97 M $296.66 M $-413,775,000 $-391,073,000 $-400,740,000
2020 $644.77 M $399.73 M $305.31 M $298.04 M $244.24 M
2019 $669.89 M $445.72 M $282.13 M $356.85 M $281.78 M
2018 $661.91 M $463.51 M $303.01 M $292.37 M $211.15 M
2017 $879.39 M $671.25 M $509.61 M $560.8 M $456.36 M
2016 $950.75 M $778.97 M $624.19 M $636.82 M $540.93 M
2015 $862.94 M $676.59 M $493.4 M $581.68 M $484.26 M
2014 $759.29 M $580.01 M $444.88 M $443.91 M $360.39 M
2013 $670.95 M $494.83 M $328.58 M $335.86 M $266.21 M
2012 $543.08 M $365.59 M $249.64 M $240.93 M $204.27 M
2011 $392.54 M $233.38 M $108.89 M $75.38 M $64.08 M
2010 $357.64 M $202.87 M $84.87 M $47.09 M $114.02 M
2009 $329.04 M $180.69 M $67.81 M $44.06 M $30.52 M
2008 $319.55 M $186.16 M $82.84 M $40.55 M $34.34 M
2007 $252.27 M $128.75 M $-17,318,000 $-81,807,000 $-82,679,000
2006 $297.74 M $169.05 M $40.47 M $7.29 M $5.68 M
2005 $284.13 M $164.73 M $18.9 M $-6,933,000 $11.08 M
2004 $315.46 M $213 M $74.69 M $72.96 M $61.16 M
2003 $211.58 M $132.11 M $61.58 M $52.96 M $44.56 M
2002 $150.13 M $95.4 M $39.26 M $30.37 M $25.99 M
2001 $103.8 M $68.46 M $27.37 M $12.57 M $10.03 M
2000 $83.79 M $52.88 M $15.13 M $7.01 M $5.54 M
1999 $66.7 M $40.4 M $10.4 M $3.7 M $2.3 M
1998 $61 M $35.1 M $7.2 M $2 M $1.4 M
1997 $56.5 M $33.8 M $7.1 M $3.3 M $2.2 M
1996 $49.6 M $30.5 M $7.1 M $3.5 M $2 M
1995 $42.1 M $26.4 M $8.5 M $5.9 M $3.4 M
1994 $28.5 M $16 M $2 M $1000 K $200 K
1993 $26.5 M $14.3 M $2.6 M $1.1 M $900 K
1992 $20.6 M $11.1 M $3.7 M $1.5 M $800 K
1991 $13.3 M $6.4 M $1.7 M $500 K $-200,000
1990 $11.8 M $5.8 M $1000 K $600 K $-200,000
1989 $9.2 M $4.1 M $500 K $400 K $100 K
1988 $8.8 M $3.8 M $300 K $400 K $